Cited by 80HIV/AIDS drug development and treatmentHIV Research and TreatmentComputational Drug Discovery Methods

Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H

Open access
Chung, Suhman, Himmel, Daniel M., Jiang, Jian-Kang, Wojtak, Krzysztof, Bauman, Joseph D., Rausch, Jason W., Wilson, Jennifer A., Beutler, John A. +3 more·2011·Journal of Medicinal Chemistry

Abstract

The α-hydroxytroplone, manicol (5,7-dihydroxy-2-isopropenyl-9-methyl-1,2,3,4-tetrahydro-benzocyclohepten-6-one), potently and specifically inhibits ribonuclease H (RNase H) activity of human immunodeficiency virus reverse transcriptase (HIV RT) in vitro. However, manicol was ineffective in reducing virus replication in culture. Ongoing efforts to improve the potency and specificity over the lead compound led us to synthesize 14 manicol derivatives that retain the divalent metal-chelating α-hydroxytropolone pharmacophore. These efforts were augmented by a high resolution structure of p66/p51 HIV-1 RT containing the nonnucleoside reverse transcriptase inhibitor (NNRTI), TMC278 and manicol in the DNA polymerase and RNase H active sites, respectively. We demonstrate here that several modified α-hydroxytropolones exhibit antiviral activity at noncytotoxic concentrations. Inclusion of RNase H active site mutants indicated that manicol analogues can occupy an additional site in or around the DNA polymerase catalytic center. Collectively, our studies will promote future structure-based design of improved α-hydroxytropolones to complement the NRTI and NNRTI currently in clinical use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm2000757

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pyrrolyl diketo acids have good potency against integrase and moderate ribonuclease H inhibition, with antiviral EC50 around micromolar, supporting dual integrase-ribonuclease H inhibitor development.

    “Among these derivatives, pyrrolyl diketo acids have shown good potency against IN and moderate inhibition of the RNH, with antiviral EC50 ~μM, demonstrating that identification of dual IN-RNH inhibitors is an attractive strategy for new drug development [83].”

    From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [83]

    The Introduction (page unavailable) lists diketo acids as a class of RNase H inhibitors. But the paper does not identify pyrrolyl diketo acids or report their integrase potency or antiviral EC50; the micromolar antiviral EC50 values in the Results are for manicol analogs. The Discussion favors developing RNase H inhibitors, not specifically dual integrase–RNase H inhibitors. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chung, S., Himmel, D. M., Jiang, J.-K., Wojtak, K., Bauman, J. D., Rausch, J. W., Wilson, J. A., Beutler, J. A., Thomas, C. J., Arnold, E., & Le Grice, S. F. J.
Affiliations
  • Frederick National Laboratory for Cancer Research (US)
  • Rutgers, The State University of New Jersey (US)
  • National Institutes of Health (US)
  • National Cancer Institute (US)
  • RT Biochemistry Section, HIV Drug Resistance Program, National Cancer Institute—Frederick, Frederick, Maryland 21702, United States
Venue
Journal of Medicinal Chemistry
Published
2011-06-02
Volume
54
Issue
13
Pages
4462-4473
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1996772034
Cited by
80
References
52
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 7 · 2017: 4 · 2016: 10 · 2015: 4 · 2014: 12 · 2013: 10 · 2012: 7
FWCI
6.72
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
  • National Institutes of Health (Z99 CA999999)
  • National Institute of Allergy and Infectious Diseases (AI-27690, R37AI027690, R01AI027690)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
Keywords
HIV-1 reverse transcriptase, non-nucleoside reverse transcriptase inhibitors, antiviral activity, structure-based drug design
MeSH terms
Rilpivirine, Benzocycloheptenes, Cations, Divalent, Cell Line, DNA-Directed DNA Polymerase, Humans, Manganese, Models, Molecular, Mutation, Nitriles, Protein Conformation, Pyrimidines, Structure-Activity Relationship, Tropolone, Virus Replication, Molecular Structure, HIV-1, Crystallography, X-Ray, Anti-HIV Agents, Catalytic Domain, HIV Reverse Transcriptase, Ribonuclease H, Human Immunodeficiency Virus, Coordination Complexes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review